Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials
Systematic review and meta-analysis of R² treatment shows improved progression-free survival in follicular lymphoma, indicating a promising chemo-free strategy.
Key Points
Rituximab plus lenalidomide showed potential to enhance progression-free survival in follicular lymphoma, especially post-adjustment.
With 1,315 patients across four trials, the risk ratio for 2-year progression-free survival was 2.05 after exclusion of an outlier.
Meta-analysis utilized PRISMA guidelines in assessing randomized controlled trials and risk of bias, emphasizing result credibility.
These findings highlight the need for further research on safety profiles and effectiveness of R² compared to standard therapies.